Genprex, Inc. (NASDAQ:GNPX) Short Interest Up 501.2% in September

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 244,700 shares, a growth of 501.2% from the August 31st total of 40,700 shares. Currently, 9.6% of the company’s stock are sold short. Based on an average trading volume of 439,400 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC lifted its stake in Genprex, Inc. (NASDAQ:GNPX) by 122.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the period. Armistice Capital LLC owned 10.39% of Genprex worth $411,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Price Performance

Shares of GNPX traded up $0.02 during midday trading on Friday, hitting $0.37. The company had a trading volume of 109,567 shares, compared to its average volume of 217,958. Genprex has a 52 week low of $0.28 and a 52 week high of $16.07. The company’s 50 day moving average price is $0.94 and its 200 day moving average price is $1.97.

Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Friday, August 9th. The company reported ($3.00) earnings per share for the quarter, missing the consensus estimate of ($2.30) by ($0.70). Equities analysts expect that Genprex will post -5.7 EPS for the current fiscal year.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.